Fundamental Data for VRX

Valeant Pharmaceuticals International is a global, publicly traded, research-based specialty pharmaceutical company that discovers, develops, manufactures and markets a broad range of pharmaceutical products.

# Employees: 2331

Address: One Enterprise,Aliso Viejo,CA,USA

Phone: 949 461-6000

Fax: 949-461-6609

Website: www.valeant.com

Email: ir@icnpharm.com

Sector: Medical

Industry: MED-DRUGS

Executive Officers

Michael J. Pearson (Chmn.; C.E.O.)

Peter J. Blott (Exec. V.P.; C.F.O.)

Robert A. Ingram (Dir.)

Lawrence N. Kugelman (Dir.)

Richard H. Koppes (Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 2/23/2010

Mean EPS (Next Qtr): $0.57

Mean EPS (Year): $2.13

Mean Estimate(Long Term): $14.84

P/E Ratio(Based on EPS estimate): 15.640

Number of Estimates: 4

Shares Performance

Period	VRX	Compare to S&P
YTD	45.33 %	20.28 %
4 Weeks	10.13 %	8.94 %
12 Weeks	30.31 %	22.85 %

Shares Information

Analyst Coverage: Y

Avg Volume: 805449

Shares Outstanding: 81M

Market Cap: $2.70B

52 Week High: $34.26

52 Week Low: $15.84

P/E Ratio: 16.080

PEG Ratio: 1.050

Split: On 3/17/1998 VRX split by factor of 1.500

Earnings Performance

EPS Growth in Last Quarter: 13.73 %

EPS Growth in Last Year: 427.27 %

Sales Growth in Last Quarter: 14.93 %

Sales Growth in Last Quarter: 30.81 %

Financials

Qtr Book Value: $8.63

Cash Flow/Share: $19.63

Change in Payout Ratio: -0.540

Price/Sales: 3.500